Abstract
The protocol described here is a streamlined, single-round method for the production of sense or antisense, labeled or unlabeled RNA from intact or partially-degraded prokaryotic or eukaryotic total RNA. By modifying the classic Eberwine method with a novel dual-promoter strategy, this approach yields high-quality, long-transcript mRNA that is highly reproducible and compatible with a wide array of modern microarray platforms, including cDNA arrays, oligonucleotide arrays, and Affymetrix GeneChip arrays.
Introduction
In genomics, clinical samples such as needle aspirates or small tumor biopsies often present a "biopsy bottleneck," yielding only 1–4 µg of total RNA—insufficient for standard microarray analysis. While the standard Eberwine method is reliable, it produces antisense RNA (aRNA). Many modern analytical tools require sense-oriented RNA. Existing alternatives for sense-start amplification are often complex, expensive, or introduce significant amplification bias, distorting the relative proportions of gene expression.
Methodology
This protocol maintains the simplicity of the Eberwine method while enabling sense-oriented output through a "dual-promoter" cDNA design:
- First-Strand Synthesis: RNA is primed with a T7-Oligo(dT) primer to create cDNA.
- Second-Strand Synthesis: Instead of random hexamers, the researchers utilized a T3N9 primer—a random nonamer attached to a T3 RNA polymerase promoter.
- In Vitro Transcription (IVT): With the T3 promoter integrated into the second strand, using T3 RNA polymerase generates RNA in the sense orientation.
This design allows researchers to choose their output orientation (antisense via T7 or sense via T3) from the same sample preparation.
Results and Validation
The method was validated using complex RNA pools from human cell lines (PA-1, CaOV-3, and U118MG) and clinical glioblastoma samples. Evaluation on 32,000-element spotted cDNA arrays confirmed high fidelity and reproducibility.
High Fidelity and Low Bias
Starting with 4 µg of total RNA, the method achieved a 130-fold amplification (averaging 26.3 µg of mRNA) in a single round. Crucially, the correlation coefficient ($r$) between amplified and unamplified RNA was 0.8009, indicating that the molecular profile remains remarkably accurate after amplification.
Benchmarking Against Commercial Kits
The protocol demonstrated superior performance compared to leading commercial alternatives. It produced significantly higher yields than the BDSmart kit and maintained a median transcript length of 794 nucleotides, which is substantially longer than the fragments produced by the RiboAmp kit (507 nt).
Discussion and Conclusion
By producing sense-oriented RNA without the need for finicky "template-switching" enzymes, this method serves as a robust, universal tool for transcriptomics. While a 130-fold amplification is ideal for microgram-scale samples, future work will explore the fidelity of this protocol in extreme low-input scenarios, such as single-cell analysis, which require even higher scales of amplification. Currently, this method offers a cost-effective and high-performance alternative to commercial kits for standard clinical and research applications.
Summary updated